search
Back to results

A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

Primary Purpose

Attention Deficit Hyperactivity Disorder

Status
Withdrawn
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
SPD465
Placebo
Sponsored by
Shire
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Attention Deficit Hyperactivity Disorder focused on measuring Attention-Deficit Hyperactivity Disorder (ADHD)

Eligibility Criteria

19 Years - 25 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject must have a valid driver's license with a minimum of 3 years of driving experience.
  2. Subject reports daily driving activity.
  3. Subject is fluent in English.
  4. Subject must be male or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol.
  5. Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities
  6. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD) established by a comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria

Exclusion criteria:

  1. Subject is significantly underweight or morbidly obese.
  2. Subject has a controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder (PTSD), psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder or other symptomatic manifestations that, in the opinion of the examining Physician, will contraindicate SPD465 treatment or confound efficacy or safety assessments.
  3. Subject with a lifetime history of psychosis or bipolar disorder.
  4. Subject with any concurrent chronic or acute illness or unstable medical condition, either treated or untreated.
  5. Subject with a history of mental retardation or a severe learning disability.
  6. Subject is naïve to ADHD treatment with methylphenidate or amphetamine.
  7. Subject has a history of glaucoma or narrow angle glaucoma.
  8. Subject has a history of seizure (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of Tourette's Disorder.
  9. Subject has known cardiac structural abnormalities as well as any other condition that may affect cardiac performance.
  10. Subject has clinically significant ECG or laboratory abnormalities at Screening or Baseline.
  11. Subject has a history of hypertension or has a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg10.
  12. Subject has used any psychoactive prescription medication or over-the-counter (OTC) medication requiring more than a 28-day washout. Hormonal contraceptives are acceptable.
  13. Subject has a documented allergy, intolerance, or documented history of non-responsivity to amphetamine.
  14. Subject currently has (or had a history within the last 6 months) a substance use disorder (excluding nicotine).
  15. Subject has taken another investigational drug or taken part in a clinical trial within the last 30 days prior to Screening.
  16. Female subject is pregnant or lactating.

Sites / Locations

  • Meridien Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

SPD465 then Placebo

Placebo then SPD465

Arm Description

Outcomes

Primary Outcome Measures

Simulated Driver Safety (DS) Score averaged over 3 driving assessments at one interim and one final visit.

Secondary Outcome Measures

Interim & final visits: Attention-Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV)
Interim & final visits: Clinical Global Impressions of Improvement (CGI-I)
Interim & final visits: Self-Rating of Simulated Driver Safety (DS) Performance Questionnaire

Full Information

First Posted
April 2, 2007
Last Updated
July 1, 2021
Sponsor
Shire
search

1. Study Identification

Unique Protocol Identification Number
NCT00458445
Brief Title
A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators
Official Title
A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Withdrawn
Why Stopped
This study was stopped by the sponsor before enrollment based on a non-safety related corporate decision.
Study Start Date
April 30, 2007 (Actual)
Primary Completion Date
June 15, 2007 (Actual)
Study Completion Date
June 15, 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shire

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether SPD465 is safe and effective in the treatment of ADHD in young adult drivers after a duration of 16 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Attention Deficit Hyperactivity Disorder
Keywords
Attention-Deficit Hyperactivity Disorder (ADHD)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SPD465 then Placebo
Arm Type
Experimental
Arm Title
Placebo then SPD465
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
SPD465
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo is a material that may look similar to SPD465, however, contains no active drug.
Primary Outcome Measure Information:
Title
Simulated Driver Safety (DS) Score averaged over 3 driving assessments at one interim and one final visit.
Time Frame
Interim visit = Week 3; Final visit = Week 7.
Secondary Outcome Measure Information:
Title
Interim & final visits: Attention-Deficit Hyperactivity Disorder Rating Scale - 4th Edition (ADHD-RS-IV)
Time Frame
Interim visit = Week 3; Final visit = Week 7.
Title
Interim & final visits: Clinical Global Impressions of Improvement (CGI-I)
Time Frame
Interim visit = Week 3; Final visit = Week 7.
Title
Interim & final visits: Self-Rating of Simulated Driver Safety (DS) Performance Questionnaire
Time Frame
Post DS Testing - Interim visit = Week 3; Post DS Testing - Final visit = Week 7.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject must have a valid driver's license with a minimum of 3 years of driving experience. Subject reports daily driving activity. Subject is fluent in English. Subject must be male or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol. Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD) established by a comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria Exclusion criteria: Subject is significantly underweight or morbidly obese. Subject has a controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder (PTSD), psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder or other symptomatic manifestations that, in the opinion of the examining Physician, will contraindicate SPD465 treatment or confound efficacy or safety assessments. Subject with a lifetime history of psychosis or bipolar disorder. Subject with any concurrent chronic or acute illness or unstable medical condition, either treated or untreated. Subject with a history of mental retardation or a severe learning disability. Subject is naïve to ADHD treatment with methylphenidate or amphetamine. Subject has a history of glaucoma or narrow angle glaucoma. Subject has a history of seizure (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of Tourette's Disorder. Subject has known cardiac structural abnormalities as well as any other condition that may affect cardiac performance. Subject has clinically significant ECG or laboratory abnormalities at Screening or Baseline. Subject has a history of hypertension or has a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg10. Subject has used any psychoactive prescription medication or over-the-counter (OTC) medication requiring more than a 28-day washout. Hormonal contraceptives are acceptable. Subject has a documented allergy, intolerance, or documented history of non-responsivity to amphetamine. Subject currently has (or had a history within the last 6 months) a substance use disorder (excluding nicotine). Subject has taken another investigational drug or taken part in a clinical trial within the last 30 days prior to Screening. Female subject is pregnant or lactating.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Study Director
Organizational Affiliation
Takeda
Official's Role
Study Director
Facility Information:
Facility Name
Meridien Research
City
Tampa
State/Province
Florida
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

We'll reach out to this number within 24 hrs